Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Auderghem – page 46

1 992 clinical trials in Auderghem, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Auderghem at a glance
1 992
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 992 trials in Auderghem

Open in trial search

Study of Lower Blood Pressure Targets Using Noradrenaline in Patients with Heart Attack-Related Cardiogenic Shock

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Noradrenaline Tartrate
  • Sponsor:Amsterdam UMC Stichting

Study on the Effectiveness and Safety of KarXT for Treating Psychosis in Patients with Alzheimer's Disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:Karuna Therapeutics Inc.

Study on the Effects of Ketamine on Therapy Intensity and Brain Pressure in Patients with Traumatic Brain Injury

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ketamine
  • Sponsor:UZ Leuven

Colorectal cancer+5

Recruiting

Study on Long-Term Safety of Trastuzumab Deruxtecan for Patients with Advanced HER2-Positive or HER2-Mutated Solid Tumors

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:Daiichi Sankyo Inc.

Study on the Effectiveness and Safety of Tinengotinib for Patients with Cholangiocarcinoma Resistant to Chemotherapy and FGFR Inhibitors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Transthera Sciences (Nanjing) Inc.

Study of Risankizumab vs. Placebo for Patients with Active Psoriatic Arthritis Who Have Not Responded Well to Previous Biologic Treatments

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on Niraparib, Carboplatin, and Paclitaxel for Advanced Ovarian Cancer Patients After Tumor Removal

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Nord Ostdeutsche Gesellschaft Fuer Gynaekologische Onkologie e.V.

Still's disease

Recruiting

Study of apremilast compared to placebo in children aged 5-17 years with juvenile psoriatic arthritis

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Apremilast
  • Sponsor:Amgen Inc.

Study on the Effectiveness of Ozanimod for Children with Moderate to Severe Ulcerative Colitis Not Responding to Usual Treatment

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Ozanimod
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study on How Tacrolimus Monohydrate and Mycophenolate Mofetil Affect Gut Bacteria in Patients with Chronic Kidney Disease After Transplant

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Mycophenolate Mofetil
  • Sponsor:Universite Catholique de Louvain

Study on the Safety of VX-670 for Adults with Myotonic Dystrophy Type 1

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:VX-670
  • Sponsor:Vertex Pharmaceuticals Inc.

Study on Preventing Infections After Esophageal Cancer Surgery Using Colistin Sulfate, Tobramycin, and Amphotericin B in Patients with Resectable Esophageal Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Amphotericin B
  • Sponsor:Radboud universitair medisch centrum Stichting

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Auderghem

What the registry says about research in the country

01 Neoplasms

In Auderghem, researchers are concentrating on lung cancer, specifically Non‑Small Cell Lung Cancer and small cell lung cancer. The two active studies compare new immune‑targeted agents such as pumitamig and obrixtamig against established therapies like pembrolizumab and standard chemotherapy, aiming to improve overall survival and disease control.

  • Comparative efficacy of novel immunotherapies
  • Evaluation of survival benefit in advanced disease
  • Biomarker‑guided patient selection (e.g., DLL3 expression)
  • Combination regimens with checkpoint inhibitors

Both trials are actively recruiting, reflecting a growing commitment in Auderghem to advance treatment options for patients with aggressive lung cancers.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.